Short Interest in Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Drops By 90.8%

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) was the target of a significant decline in short interest in May. As of May 15th, there was short interest totaling 75,959 shares, a decline of 90.8% from the April 30th total of 821,485 shares. Currently, 6.2% of the company’s shares are short sold. Based on an average daily volume of 703,441 shares, the days-to-cover ratio is currently 0.1 days.

Aspire Biopharma Price Performance

Shares of NASDAQ ASBP traded down $0.12 during trading on Friday, hitting $5.41. The stock had a trading volume of 97,352 shares, compared to its average volume of 361,398. Aspire Biopharma has a 12 month low of $3.31 and a 12 month high of $1,050.36. The firm has a fifty day moving average of $15.58 and a two-hundred day moving average of $61.49. The company has a market capitalization of $7.03 million, a PE ratio of -0.05 and a beta of 0.21.

Aspire Biopharma (NASDAQ:ASBP) last announced its earnings results on Friday, May 15th. The company reported ($20.57) earnings per share for the quarter. The firm had revenue of $0.03 million during the quarter.

Institutional Investors Weigh In On Aspire Biopharma

Several large investors have recently added to or reduced their stakes in the company. Jane Street Group LLC boosted its holdings in Aspire Biopharma by 2,252.1% in the 4th quarter. Jane Street Group LLC now owns 688,143 shares of the company’s stock worth $91,000 after buying an additional 658,886 shares during the period. XTX Topco Ltd increased its holdings in Aspire Biopharma by 853.2% during the 4th quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock worth $35,000 after acquiring an additional 237,620 shares during the period. Finally, CIBC Bancorp USA Inc. bought a new stake in Aspire Biopharma during the 3rd quarter worth approximately $28,000. Hedge funds and other institutional investors own 19.17% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Aspire Biopharma in a report on Monday, April 20th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

About Aspire Biopharma

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.